	US 12,427,127 B2
	Carmustine formulation
Deepak Pragjibhai Gondaliya, Pune (IN); Hiren Pravinbhai Patel, Pune (IN); Haresh Ishwarbhai Patel, Pune (IN); and Mukund Keshav Gurjar, Pune (IN)
Assigned to EMCURE PHARMACEUTICALS LIMITED, Pune (IN)
Appl. No. 16/981,344
Filed by EMCURE PHARMACEUTICALS LIMITED, Pune (IN)
PCT Filed Mar. 30, 2019, PCT No. PCT/IB2019/052644 § 371(c)(1), (2) Date Sep. 16, 2020, PCT Pub. No. WO2019/193477, PCT Pub. Date Oct. 10, 2019.
Claims priority of application No. 2018210129964 (IN), filed on Apr. 5, 2018.
Prior Publication US 2021/0361599 A1, Nov. 25, 2021
Int. Cl. A61K 31/17 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/19 (2006.01); A61K 9/51 (2006.01); A61K 47/14 (2017.01); A61K 47/34 (2017.01); A61P 35/00 (2006.01)

CPC A61K 31/17 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1075 (2013.01); A61K 9/19 (2013.01); A61K 47/14 (2013.01); A61K 47/34 (2013.01); A61P 35/00 (2018.01)]

5 Claims

1. A drug composition comprising: (i) 0.1 wt % to 50 wt % of carmustine: (ii) 1 wt % to 70 wt % of a combination of phosphatidylcholine and sodium cholesteryl sulfate: (iii) 1 wt % to 60 wt % of poly (lactic-co-glycolic acid) (PLGA): (iv) sucrose and (v) water wherein the ratio of carmustine to PLGA ranges from 1:3 to 1:6 weight-per-weight (w/w) and the composition is a nano-suspension.